These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 15660727)
1. Insulin treatment and cardiovascular disease; friend or foe? A point of view. Muis MJ; Bots ML; Grobbee DE; Stolk RP Diabet Med; 2005 Feb; 22(2):118-26. PubMed ID: 15660727 [TBL] [Abstract][Full Text] [Related]
2. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184 [TBL] [Abstract][Full Text] [Related]
3. [Does targeted therapy of type 2 diabetes prevent cardiovascular incidents?]. Leschke M Med Klin (Munich); 2003 Oct; 98 Suppl 1():12-6. PubMed ID: 14694836 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Strowig SM; Raskin P Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007 [TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. Ragucci E; Zonszein J; Frishman WH Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628 [TBL] [Abstract][Full Text] [Related]
7. Refining basal insulin therapy: what have we learned in the age of analogues? Devries JH; Nattrass M; Pieber TR Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418 [TBL] [Abstract][Full Text] [Related]
8. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Currie CJ; Johnson JA Diabetes Obes Metab; 2012 Jan; 14(1):1-4. PubMed ID: 21736688 [TBL] [Abstract][Full Text] [Related]
9. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. Roman G; Hancu N Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921 [TBL] [Abstract][Full Text] [Related]
10. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Schiel R; Müller UA; Braun A; Stein G; Kath R Eur J Med Res; 2005 Aug; 10(8):339-44. PubMed ID: 16131475 [TBL] [Abstract][Full Text] [Related]
11. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E; Minuto F; Colao A; Ferone D Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [TBL] [Abstract][Full Text] [Related]
12. [Should insulin treatment be avoided? Blood sugar is not everything in type 2 diabetes]. Carlsen SM Tidsskr Nor Laegeforen; 1995 Aug; 115(18):2271-5. PubMed ID: 7652727 [TBL] [Abstract][Full Text] [Related]
13. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance. Lebovitz HE J Indian Med Assoc; 2008 Nov; 106(11):724-6. PubMed ID: 19368098 [TBL] [Abstract][Full Text] [Related]
14. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Fonseca VA Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042 [TBL] [Abstract][Full Text] [Related]
15. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Schramm TK; Gislason GH; Køber L; Rasmussen S; Rasmussen JN; Abildstrøm SZ; Hansen ML; Folke F; Buch P; Madsen M; Vaag A; Torp-Pedersen C Circulation; 2008 Apr; 117(15):1945-54. PubMed ID: 18378618 [TBL] [Abstract][Full Text] [Related]
16. The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes. Khalangot M; Tronko M; Kravchenko V; Kulchinska J; Hu G Diabetes Res Clin Pract; 2008 Oct; 82(1):139-47. PubMed ID: 18703252 [TBL] [Abstract][Full Text] [Related]
17. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870 [TBL] [Abstract][Full Text] [Related]
18. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG; Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424 [TBL] [Abstract][Full Text] [Related]
19. A pilot study to examine the feasibility of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes. Marbury TC; Schwartz S; Rosenberg MA; Jariwala N; Becker RH; Johnston PS Exp Clin Endocrinol Diabetes; 2008 May; 116(5):282-8. PubMed ID: 18484560 [TBL] [Abstract][Full Text] [Related]
20. [Increased cardiovascular risk in patients with type 2 diabetes treated with sulfonylurea?]. Asvold BO; Jonsbu M; Grill V Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2560-4. PubMed ID: 11070997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]